ACRS
Price
$4.34Alerts
Change
+$0.19 (+4.58%)
Updated
Nov 11 closing price
Capitalization
574.08M
106 days until earnings call
Intraday BUY SELL Signals
KYTX
Price
$5.12Alerts
Change
+$0.04 (+0.79%)
Updated
Nov 11 closing price
Capitalization
301.8M
Earnings call today
Intraday BUY SELL Signals
Interact to see
Advertisement

ACRS vs KYTX

ACRS vs KYTX Comparison Chart in %
View a ticker or compare two or three
VS
ACRS vs. KYTX commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRS is a Hold and KYTX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ACRS with price predictions
Nov 10, 2026

Momentum Indicator for ACRS turns positive, indicating new upward trend

ACRS saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In 80 of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACRS's RSI Oscillator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for ACRS just turned positive on October 21, 2026. Looking at past instances where ACRS's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.

Following a +17.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRS advanced for three days, in 222 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

ACRS broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ACRS entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.608) is normal, around the industry mean (3.498). P/E Ratio (-6.724) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (83.333) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. ACRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for KYTX with price predictions
Nov 10, 2026

KYTX's RSI Oscillator ascends from oversold territory

The RSI Oscillator for KYTX moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 19 similar instances when the indicator left oversold territory. In 18 of the 19 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 29 of 33 cases where KYTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

Following a +12.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where KYTX advanced for three days, in 122 of 137 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

KYTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KYTX as a result. In 44 of 52 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for KYTX turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 24 similar instances when the indicator turned negative. In 23 of the 24 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KYTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for KYTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. KYTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.823) is normal, around the industry mean (3.498). P/E Ratio (-1.671) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KYTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ACRS: Fundamental Ratings
ACRS
OUTLOOK RATING
1..100
30
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
48
P/E GROWTH RATING
1..100
15
SEASONALITY SCORE
1..100
33

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACRSKYTX
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
89%
Declines
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 9 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ACRS: $4.15 vs. KYTX: $5.08)
Brand notoriety: ACRS and KYTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACRS: 41% vs. KYTX: 48%
Market capitalization -- ACRS: $574.08M vs. KYTX: $301.8M
ACRS [@Biotechnology] is valued at $574.08M. KYTX’s [@Biotechnology] market capitalization is $301.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACRS’s FA Score shows that 1 FA rating(s) are green while KYTX’s FA Score has 1 green FA rating(s).

  • ACRS’s FA Score: 1 green, 4 red.
  • KYTX’s FA Score: 1 green, 4 red.
According to our system of comparison, ACRS is a better buy in the long-term than KYTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACRS’s TA Score shows that 4 TA indicator(s) are bullish while KYTX’s TA Score has 4 bullish TA indicator(s).

  • ACRS’s TA Score: 4 bullish, 4 bearish.
  • KYTX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ACRS and KYTX are a good buy in the short-term.

Price Growth

ACRS (@Biotechnology) experienced а +10.96% price change this week, while KYTX (@Biotechnology) price change was -1.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

ACRS is expected to report earnings on Feb 25, 2027.

KYTX is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ACRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACRS has been closely correlated with CRVS. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if ACRS jumps, then CRVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACRS
1D Price
Change %
ACRS100%
-2.12%
CRVS - ACRS
67%
Closely correlated
+0.18%
STRRP - ACRS
52%
Loosely correlated
+0.89%
QUCY - ACRS
40%
Loosely correlated
+0.98%
UFPT - ACRS
39%
Loosely correlated
-1.51%
KYTX - ACRS
38%
Loosely correlated
-1.74%
More

KYTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, KYTX has been loosely correlated with IMNM. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if KYTX jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KYTX
1D Price
Change %
KYTX100%
-1.74%
IMNM - KYTX
59%
Loosely correlated
-3.67%
FDMT - KYTX
59%
Loosely correlated
-0.16%
EDIT - KYTX
50%
Loosely correlated
-8.91%
SANA - KYTX
49%
Loosely correlated
-1.42%
TSHA - KYTX
49%
Loosely correlated
-2.17%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SCAG1.010.02
+2.02%
Scage Future
BHE63.640.32
+0.51%
Benchmark Electronics
CPT99.89-0.39
-0.39%
Camden Property Trust
AQST3.52-0.02
-0.56%
Aquestive Therapeutics
KAPA0.47-0.03
-6.14%
Kairos Pharma Ltd